NASDAQ:MCRB

Seres Therapeutics - MCRB Stock Forecast, Price & News

$6.13

-0.24 (-3.77%)

(As of 09/29/2022 10:53 AM ET)

Add

Compare

Today's Range: $6.08
▼
$6.30
50-Day Range: $3.65
▼
$7.20
52-Week Range: $2.50
▼
$11.69

Volume: 7,019 shs
Average Volume: 1.30 million shs
Market Capitalization: $760.55 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.33

Seres Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 144.6% Upside
$15.33 Price Target
Short Interest: Healthy
2.72% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.14
Upright™ Environmental Score
News Sentiment: 0.91
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$27.53 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($2.12) to ($1.06) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.64 out of 5 stars

Medical Sector

109th out of 1,096 stocks

Pharmaceutical Preparations Industry

35th out of 548 stocks

3.5

Analyst's Opinion

Consensus Rating
Seres Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.33, Seres Therapeutics has a forecasted upside of 144.6% from its current price of $6.27.
Amount of Analyst Coverage
Seres Therapeutics has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
2.72% of the outstanding shares of Seres Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Seres Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Seres Therapeutics has recently decreased by 1.17%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Seres Therapeutics does not currently pay a dividend.
Dividend Growth
Seres Therapeutics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Seres Therapeutics has received a 71.59% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for infectious diseases", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Seres Therapeutics is -1.14.

2.7

News and Social Media Coverage

News Sentiment
Seres Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Seres Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 14 people have searched for MCRB on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Seres Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Seres Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $27,525,465.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 4.20% of the stock of Seres Therapeutics is held by insiders.
Percentage Held by Institutions
96.09% of the stock of Seres Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Seres Therapeutics are expected to grow in the coming year, from ($2.12) to ($1.06) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Seres Therapeutics is -5.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Seres Therapeutics is -5.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Seres Therapeutics has a P/B Ratio of 4.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Seres Therapeutics (NASDAQ:MCRB) Stock

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Receive MCRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MCRB Stock News Headlines

September 22, 2022 | reuters.com

U.S. FDA panel recommends Ferring's fecal transplant therapy

September 22, 2022 | finance.yahoo.com

Limit lab construction in the world's biotech capital? A Cambridge proposal could do just that.

September 19, 2022 | nasdaq.com

Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

September 8, 2022 | finance.yahoo.com

Seres Therapeutics to Present at World Anti-Microbial Resistance Congress

September 7, 2022 | markets.businessinsider.com

Why Seres Therapeutics Shares Are Popping Off Today

September 7, 2022 | nasdaq.com

Seres Completes Rolling BLA Submission To FDA For SER-109 For Prevention Of RCDI

September 7, 2022 | finance.yahoo.com

Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection

August 29, 2022 | finance.yahoo.com

Calculating The Intrinsic Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)

August 8, 2022 | finance.yahoo.com

Analysts Are Betting On Seres Therapeutics, Inc. (NASDAQ:MCRB) With A Big Upgrade This Week

August 6, 2022 | nasdaq.com

Broker Revenue Forecasts For Seres Therapeutics, Inc. (NASDAQ:MCRB) Are Surging Higher

August 4, 2022 | finance.yahoo.com

Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference

August 3, 2022 | finance.yahoo.com

Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

August 3, 2022 | finance.yahoo.com

Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue Estimates

July 28, 2022 | finance.yahoo.com

Seres Therapeutics to Host Second Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2022

July 19, 2022 | finance.yahoo.com

Do Institutions Own Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares?

July 14, 2022 | nasdaq.com

Seres Therapeutics Rallies 14% as Insider Flagship Pioneering Increases Stake

July 9, 2022 | seekingalpha.com

Daily Biotech/Pharma Pulse: July 7

June 30, 2022 | seekingalpha.com

Seres Therapeutics stock slips on $100M stock offering

June 30, 2022 | nasdaq.com

Seres Therapeutics Announces $100 Mln Direct Offering Of Stock

June 30, 2022 | finance.yahoo.com

Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock

June 19, 2022 | finance.yahoo.com

Seres Therapeutics (NASDAQ:MCRB shareholders incur further losses as stock declines 12% this week, taking one-year losses to 87%

June 18, 2022 | seekingalpha.com

MCRB,CKPT and RDBX among pre market gainers.

June 7, 2022 | finance.yahoo.com

Seres Therapeutics Touts New Safety Data, Plans First FDA Approval For Microbiome Drug

June 7, 2022 | finance.yahoo.com

Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection

May 22, 2022 | finance.yahoo.com

Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MCRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MCRB Company Calendar

Last Earnings: 8/03/2022
Today: 9/29/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MCRB
CUSIP: N/A
CIK: 1609809
Web: www.serestherapeutics.com
Phone: (617) 945-9626
Fax: N/A
Employees: 333
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $15.33
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $9.00
Forecasted Upside/Downside: +150.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.14)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-65,580,000.00
Net Margins: -75.48%
Pretax Margin: -75.48%
Return on Equity: -100.32%
Return on Assets: -30.69%

Debt

Debt-to-Equity Ratio: 2.20
Current Ratio: 2.35
Quick Ratio: 2.35

Sales & Book Value

Annual Sales: $144.93 million
Price / Sales: 5.25
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.43 per share
Price / Book: 4.29

Miscellaneous

Outstanding Shares: 124,070,000
Free Float: 118,861,000
Market Cap: $760.55 million
Optionable: Optionable
Beta: 3.03

Key Executives

Mr. Eric D. Shaff M.B.A. (Age 46)
Pres, CEO & Director
Comp: $953.1k

Mr. David A. Arkowitz M.B.A. (Age 61)
Exec. VP, CFO & Head of Bus. Devel.
Comp: $603.33k

Dr. Matthew R. Henn Ph.D. (Age 47)
Exec. VP & Chief Scientific Officer
Comp: $591.78k

Dr. David S. Ege Ph.D. (Age 48)
Exec. VP & Chief Technology Officer

Mr. Carlo Tanzi Ph.D.
Investor Relations Officer

Mr. Thomas J. DesRosier Esq. (Age 67)
J.D., Chief Legal Officer, Exec. VP & Sec.

Ms. Kristin Ainsworth
Sr. VP of Corp. Communications

Mr. Jeff York
VP of HR

Ms. Paula A. Cloghessy SHRM-SCP (Age 50)
SPHR, Exec. VP & Chief People Officer

Dr. Lisa von Moltke M.D. (Age 63)
Exec. VP & Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MCRB Stock - Frequently Asked Questions

Should I buy or sell Seres Therapeutics stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MCRB shares.
View MCRB analyst ratings or view top-rated stocks.
What is Seres Therapeutics' stock price forecast for 2022?: 3 brokerages have issued twelve-month price objectives for Seres Therapeutics' stock. Their MCRB share price forecasts range from $9.00 to $25.00. On average, they anticipate the company's stock price to reach $15.33 in the next year. This suggests a possible upside of 140.7% from the stock's current price.
View analysts price targets for MCRB or view top-rated stocks among Wall Street analysts.
How have MCRB shares performed in 2022?: Seres Therapeutics' stock was trading at $8.33 at the start of the year. Since then, MCRB shares have decreased by 23.5% and is now trading at $6.37.
View the best growth stocks for 2022 here.
When is Seres Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our MCRB earnings forecast.
How were Seres Therapeutics' earnings last quarter?: Seres Therapeutics, Inc. (NASDAQ:MCRB) released its quarterly earnings results on Wednesday, August, 3rd. The biotechnology company reported ($0.70) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $0.12. The biotechnology company had revenue of $1.22 million for the quarter, compared to analyst estimates of $6.03 million. Seres Therapeutics had a negative trailing twelve-month return on equity of 100.32% and a negative net margin of 75.48%.
What other stocks do shareholders of Seres Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did Seres Therapeutics IPO?: (MCRB) raised $101 million in an IPO on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.
What is Seres Therapeutics' stock symbol?: Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."
How do I buy shares of Seres Therapeutics?: Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Seres Therapeutics' stock price today?: One share of MCRB stock can currently be purchased for approximately $6.37.
How much money does Seres Therapeutics make?: Seres Therapeutics (NASDAQ:MCRB) has a market capitalization of $790.33 million and generates $144.93 million in revenue each year. The biotechnology company earns $-65,580,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis.
How many employees does Seres Therapeutics have?: The company employs 333 workers across the globe.
How can I contact Seres Therapeutics?: Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.serestherapeutics.com. The biotechnology company can be reached via phone at (617) 945-9626 or via email at ctanzi@serestherapeutics.com.

This page (NASDAQ:MCRB) was last updated on 9/29/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Seres Therapeutics - MCRB Stock Forecast, Price & News

Seres Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows